BI Shutters Ben Venue in the Face of Remediation Price Tag

Boehringer Ingelheim (BI) has decided to close Ben Venue Laboratories, its beleaguered generic injectable drugmaking unit, by the end of the year, saying the subsidiary’s remediation efforts will total about $1 billion and are not worth the cost of keeping it open.
Drug Industry Daily